Stifel dropped the company goal On Maravai Lifesciences (Crumbly) up to $ 5 from $ 10 and holds a shopping rating on the stock. The company notes the Q4 revenue appeared in the amount of $ 1 million, while EBITDA fell by $ 7 million. As for the guide, the chances of management are significantly below the street, but exclude all orders to clean a large amount. Stifel believes that the company is at the place where the transition from the Kovid to non-Nevid demand, China is the insecurity and opacity of the key area of the model, enables the situation of low visibility. Maravai looks washed from $ 2 to $ 3, but it remains to buy with low reliability until greater clarity is achieved and better growth is materialized, the company adds.
Published first on Thefly -Real -time short source, on the market that moves in breaking the financial news. Try now >>
See today’s best stocks on Tipranks >>
Read more about the crumb:
Questions or comments about the article? Write at editor@tipranks.com
